Skip to main content

Corporate Governance

Solidion Names CEO Jaymes Winters as Chairman, Adds Lead Director

Solidion Names CEO Jaymes Winters as Chairman, Adds Lead Director

Dallas – September 21, 2026 -- Solidion Technology, Inc. (NASDAQ: STI) has combined its Chairman and CEO roles, appointing Jaymes Winters to the dual position effective September 16, 2026, while naming Mark N. Schwartz as Lead Independent Director.

Winters adds Chairman title to CEO role effective September 16

Winters, who brings more than 15 years of chief executive experience across oil and gas, telecommunications and retail, will retain the CEO title while assuming board chairmanship. He previously served as CEO of Nubia Brand International Corp, a special purpose acquisition company, and founded United Energy Inc., which he grew to nearly $100 million in revenue. Winters also taught business strategy, mergers and acquisitions, and venture capital for more than 9 years as an adjunct professor at Portland State University's School of Business.

BioMarin Adds Bristol Myers Squibb Research Chief Robert Plenge to Board

BioMarin Adds Bristol Myers Squibb Research Chief Robert Plenge to Board

San Rafael, Calif. – September 17, 2026 -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has appointed Robert Plenge, M.D., Ph.D., to its Board of Directors, effective September 10, 2026.

Plenge brings nine-site global research oversight from Bristol Myers Squibb

Dr. Plenge currently serves as Executive Vice President, Chief Research Officer and Head of Research at Bristol Myers Squibb, directing scientific operations across nine research sites worldwide. He joined the company in November 2019 through its acquisition of Celgene Corp., where he had led the immunology and inflammation portfolio in research and early development.